Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies |
| |
| Authors: | Fei Song Robert Fux Lisette B Provacia Asisa Volz Markus Eickmann Stephan Becker Albert D M E Osterhaus Bart L Haagmans Gerd Sutter |
| |
| Institution: | Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Munich, Munich, Germanya;Department of Viroscience, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlandsb;Institute of Virology, Philipps University Marburg, Marburg, Germanyc;German Centre for Infection Research (DZIF)d‡ |
| |
| Abstract: | Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a causative agent of severe respiratory disease in humans. Here, we constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for clinical testing. Vaccinated mice produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVA-MERS-S may serve for further development of an emergency vaccine against MERS-CoV. |
| |
| Keywords: | |
|
|
